Life Sciences Daily Summary
Life Sciences Daily Summary: What Happened on November 12, 2026
Blackstone to fund up to $1.5 billion of Pfizer’s obesity-drug development
Neurosterix raised $105 million for a schizophrenia drug. Lilly added two medicines to Hims & Hers, and the FDA ordered an eye-risk warning across GLP-1 labels.
Today in brief
Blackstone Life Sciences will cover up to $1.5 billion of Pfizer’s berobenatide development costs through 2028, with possible payments tied to approval and sales milestones.12 Neurosterix raised $105 million to advance its schizophrenia candidate NTX-253 toward Phase 2 after completing Phase 1 studies.3 Lilly will offer Zepbound and Foundayo through Hims & Hers at Lilly’s self-pay prices for eligible patients with prescriptions.4 The FDA directed makers of all GLP-1 receptor agonists to add a warning about a rare risk of sudden vision loss.4 Biopharma layoffs affected 43% more workers in October than in October 2025, while reported cuts through October remained below 2025’s total.5
Blackstone will share Pfizer’s berobenatide development costs
Blackstone Life Sciences agreed to fund up to $1.5 billion of Pfizer’s berobenatide development costs through 2028.12 The investigational monthly GLP-1 drug is being studied for chronic weight management. Pfizer retains control of development decisions.12
Blackstone receives no ownership or drug rights, but may receive payments if berobenatide gains US approval for chronic weight management and meets specified sales goals.12 In a Phase 2b trial, monthly 4.8-milligram dosing produced up to 12.3% greater weight loss than placebo at 28 weeks.26 Pfizer has 10 berobenatide Phase 3 studies underway or planned.26
Neurosterix raises $105 million for its schizophrenia program
Neurosterix raised $105 million in a Series B round led by RTW Investments to advance NTX-253 toward Phase 2.3 The company said it completed Phase 1 studies in healthy volunteers and people with stable schizophrenia in October.3
NTX-253 is an oral positive allosteric modulator of the muscarinic M4 receptor, designed to amplify the receptor’s response to acetylcholine.3 Neurosterix said Phase 1 pharmacokinetic data support once-daily dosing. The drug’s clinical efficacy has not yet been demonstrated.3
Lilly medicines will be available through Hims & Hers
Lilly and Hims & Hers agreed to make Zepbound and Foundayo available through the telehealth company’s platform at Lilly’s self-pay prices.4 The offer is for eligible patients who receive prescriptions from licensed providers.4
Novo Nordisk made Wegovy and Ozempic available through Hims & Hers in March. That deal also ended a patent lawsuit against the telehealth company.4 Hims & Hers says it has not sold compounded versions of Lilly’s GLP-1 medicines and has pledged not to do so.4
FDA orders eye-risk warning across GLP-1 drug labels
The FDA directed manufacturers of all GLP-1 receptor agonists to add a warning about a possible increased risk of nonarteritic anterior ischemic optic neuropathy, or NAION.4 NAION is an uncommon condition that can cause sudden, painless vision loss in one eye.4
The FDA’s review followed a July 2024 observational study. The agency found that NAION remained rare in the clinical and real-world evidence it assessed.4 The FDA is asking prescribers to tell patients to report sudden vision changes promptly.4
October layoffs rose year over year, but 2026 cuts remain lower
Fifteen biopharma companies made or planned layoffs in October. The number of affected workers was 43% higher than in October 2025.5 October was the first month of 2026 in which both the number of employers reporting or planning cuts and the affected-worker total exceeded the same month a year earlier.5
Through October, 99 companies had cut or planned cuts affecting 19,538 people, compared with 200 companies and 43,242 workers in all of 2025.5 Artiva Biotherapeutics said it would cut 94% of its workforce and stop developing AlloNK after two patient deaths and concerns about the duration of clinical responses.5 Caribou Biosciences attributed its cuts and decision to stop advancing its clinical-stage pipeline to a financing freeze in the CAR T field.5